Retinopathy News and Research

RSS

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted for standard review the Company's supplemental Biologics License Application for EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema.

18 Dec 2013

Pre-existing diabetes in pregnant women doubles risk of death of infants

New research shows that pre-existing diabetes in pregnant women greatly increases the risk of death of their unborn fetus by around four-and-a-half times compared with pregnant women without diabetes, and also almost doubles the risk of death of infants after birth.

28 Nov 2013

Patients who undergo gastric bypass less likely to have risk of heart attack and stroke

New research from the Cleveland Clinic shows most patients with diabetes and obesity who undergo gastric bypass not only experience remission of their diabetes and lose significant weight, but they also reduce their risk of having a heart attack by 40 percent and their risk for suffering a stroke by 42 percent, over a 10-year time horizon.

16 Nov 2013

Gastric bypass dramatically improves multiple cardiovascular risk factors in the long term

15 Nov 2013

Study investigates association between preterm birth and later retinal detachment

Children born extremely prematurely have up to a 19 times greater risk of retinal detachment later in life than peers born at term, according to a Swedish study published this month in Ophthalmology, the journal of the American Academy of Ophthalmology.

8 Nov 2013

Endocrine Society publishes Clinical Practice Guideline on diabetes and pregnancy

The Endocrine Society today issued a Clinical Practice Guideline to help health care professionals provide the best care to pregnant women who have diabetes.

6 Nov 2013

Oligomeric proanthocyanidin has protective effect on retinal ganglion cells, shows study

The death of retinal ganglion cells is a hallmark of many optic neurodegenerative diseases such as glaucoma and retinopathy. Oxidative stress is one of the major reasons to cause the cell death.

4 Nov 2013

REDDSTAR plenary meeting to be held in Berlin on Nov 5 and 6

'Diabetes- can stem cells help?' is a free, public event that will be held on Monday, 4 November 2013 from 19:00- 20:30 at The Ruin located within the Berlin Museum of Medical History, Charité. Diabetes and stem cell researchers from around Europe will assemble for a REDDSTAR plenary meeting hosted by Charité in Berlin on November 5 and 6th.

30 Oct 2013

NEI-funded study explores methods to improve diagnosis, treatment of common eye diseases

If you've ever been sleep-deprived, you've probably had a firsthand glimpse of the blood vessels in your eyes. But what you haven't seen—and what many eye care professionals cannot see as well as they would like—are the vessels closest to the retina, the light-sensitive tissue at the back of the eye.

29 Oct 2013

Promising technique for treating eye disease proves effective in preclinical studies

A promising technique for treating human eye disease has proven effective in preclinical studies and may lead to new treatments to prevent blindness, according to experiments conducted at The Scripps Research Institute in La Jolla, California.

23 Oct 2013

Diabetic retinopathy incidence in upward trend

Retinal damage is one of the most common complications of diabetes, affecting about 90 percent of type 1 diabetics and 75 percent of type 2 diabetics. According to the World Health Organization (WHO), diabetic retinopathy is the leading cause of blindness in adults of working age, and its incidence is showing an upward trend.

8 Oct 2013

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

...

2 Oct 2013

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

...

1 Oct 2013

Sun Pharma, Intrexon partner to develop controllable gene-based therapies for ocular diseases

Sun Pharmaceutical Industries Ltd., an international specialty pharmaceutical company focused on chronic diseases, through its subsidiary, and Intrexon Corporation, a leader in synthetic biology, today announced the formation of a joint venture to develop controllable gene-based therapies for the treatment of ocular diseases that cause partial or total blindness in millions of people worldwide.

1 Oct 2013

New laser provides better treatment for eye diseases in diabetes patients

A new laser is helping experts at the Truhlsen Eye Institute at the University of Nebraska Medical Center provide better treatment for eye diseases. This advanced laser can prevent blindness for some patients with serious conditions.

24 Sep 2013

ThromboGenics, Bicycle to develop and commercialize novel drugs for ophthalmic diseases

ThromboGenics NV, a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that it has entered into a collaboration and license agreement with Bicycle Therapeutics to develop and commercialize novel drugs inhibiting a specific target for the treatment of ophthalmic diseases, such as diabetic macular edema.

5 Sep 2013

Omega-3 rich oils improve membrane fluidity in retina cells and help fight age-related eye diseases

Scientists working at the Research Center on Aging at the Health and Social Services Centre - University Institute of Geriatrics of Sherbrooke (CSSS-IUGS) have been studying strategies for protecting retinal pigment epithelium (RPE) cells.

16 Aug 2013

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that in the Phase 3 VIVID-DME and VISTA-DME trials of EYLEA (aflibercept) Injection for the treatment of diabetic macular edema, EYLEA 2 milligrams (mg) dosed monthly and EYLEA 2 mg dosed every two months (after 5 initial monthly injections) achieved the primary endpoint of a significantly greater improvement in best-corrected visual acuity from baseline compared to laser photocoagulation at 52 weeks.

6 Aug 2013

University of Florida receives RPB Sanders Construction grant

Research to Prevent Blindness has awarded a prestigious, one-time laboratory grant of $600,000 to the Department of Ophthalmology at the University of Florida, College of Medicine. The newly created laboratory will be permanently named the RPB Mildred Krahmer Sanders and William Clifford Sanders Laboratory for Vision Research.

20 Jul 2013

Researchers discover new protein that encourages ‘bad’ blood vessel growth

The discovery of a protein that encourages blood vessel growth, and especially 'bad' blood vessels - the kind that characterise diseases as diverse as cancer, age-related macular degeneration and rheumatoid arthritis - has been reported in the journal Nature.

18 Jul 2013

Retinopathy News and Research

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Pre-existing diabetes in pregnant women doubles risk of death of infants

Patients who undergo gastric bypass less likely to have risk of heart attack and stroke

Gastric bypass dramatically improves multiple cardiovascular risk factors in the long term

Study investigates association between preterm birth and later retinal detachment

Endocrine Society publishes Clinical Practice Guideline on diabetes and pregnancy

Oligomeric proanthocyanidin has protective effect on retinal ganglion cells, shows study

REDDSTAR plenary meeting to be held in Berlin on Nov 5 and 6

NEI-funded study explores methods to improve diagnosis, treatment of common eye diseases

Promising technique for treating eye disease proves effective in preclinical studies

Diabetic retinopathy incidence in upward trend

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

Sun Pharma, Intrexon partner to develop controllable gene-based therapies for ocular diseases

New laser provides better treatment for eye diseases in diabetes patients

ThromboGenics, Bicycle to develop and commercialize novel drugs for ophthalmic diseases

Omega-3 rich oils improve membrane fluidity in retina cells and help fight age-related eye diseases

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

University of Florida receives RPB Sanders Construction grant

Researchers discover new protein that encourages ‘bad’ blood vessel growth

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Latest News